September 22, 2014 3:40 PM ET

Pharmaceuticals

Company Overview of Zyngenia, Inc.

Executive Profile

Peter A. Kiener D.Phil.

Chief Executive Officer, President and Director, Zyngenia, Inc.
AgeTotal Calculated CompensationThis person is connected to 6 Board Members in 6 different organizations across 10 different industries.

See Board Relationships
62--

Background

Dr. Peter A. Kiener, D.Phil. is a Co-Founder of Zyngenia, Inc. Dr. Kiener serves as Chief Executive Officer and President of Zyngenia, Inc. and leads business and drug development efforts. Dr. Kiener has been Chief Scientific Officer of Ambrx, Inc. since August 2013. Dr. Kiener serves as a Board Observer of Virdante Pharmaceuticals, Inc. He served as an Executive Vice President of Research at MedImmune Inc. since February 2008 and its Head of research and development. ...

Corporate Headquarters

21 Firstfield Road
Gaithersburg, Maryland 20878

United States

Phone: 410-467-1176
Fax: --

Board Members Memberships

Former Director
Board Observer
Chief Executive Officer, President and Director
Chairman

Education

PhD
University of Oxford
BS
Lancaster University

Other Affiliations

Annual Compensation

There is no Annual Compensation data available.

Stocks Options

There is no Stock Options data available.

Total Compensation

There is no Total Compensation data available.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

There is no Competitor Compensation data available.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Zyngenia, Inc., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.